Clinical trial
Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI…
NCT00410787 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00410787 |
|---|---|
| Title | Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain |
| Official title | Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Analgesics, Opioid, Pain |
| Intervention type | Drug |
| Interventions | OROS hydromorphone HCI (slow release) |
| Enrollment | 68 |
| Completion | Apr 1, 2002 |
| First posted | Dec 13, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: